# FAERS Submission Application - System Overview

## Document Purpose

This document provides Claude Code with the complete context for designing and implementing the FAERS (FDA Adverse Event Reporting System) Submission Application. This is a phased development project where each phase builds upon previous phases to create a comprehensive pharmacovigilance solution for biotech companies.

---

## 1. Business Context

### 1.1 What is FAERS?

FAERS (FDA Adverse Event Reporting System) is the FDA's database for storing adverse event reports and medication error reports submitted to the FDA. Pharmaceutical and biotech companies are legally required to submit safety reports when they become aware of adverse events related to their products.

### 1.2 Regulatory Requirements

| Requirement | Description | Deadline |
|-------------|-------------|----------|
| **Expedited Reports** | Serious, unexpected adverse reactions | 15 calendar days from receipt |
| **Non-Expedited Reports** | Other adverse events | Periodic (quarterly/annually) |
| **E2B(R3) Standard** | ICH standard for electronic ICSR transmission | Mandatory by April 1, 2026 |
| **21 CFR Part 11** | FDA regulation for electronic records/signatures | Always required |

### 1.3 Target Users

- **Small Biotech**: 1-5 safety professionals, low volume (<100 reports/year)
- **Mid-size Biotech**: 5-20 safety professionals, moderate volume (100-1000 reports/year)
- **Large Pharma/CRO**: 20+ safety professionals, high volume (1000+ reports/year)

---

## 2. Application Vision

### 2.1 Product Goals

Build a comprehensive FAERS submission application that:

1. Enables compliant E2B(R3) ICSR creation and submission to FDA
2. Supports the full lifecycle from case intake to FDA acknowledgment
3. Scales from single-user to enterprise multi-user environments
4. Maintains regulatory compliance (21 CFR Part 11, HIPAA)
5. Integrates with existing pharmacovigilance ecosystems

### 2.2 Key Differentiators

- **Phased Delivery**: Each phase is independently valuable and deployable
- **Compliance-First**: Built-in regulatory compliance from the ground up
- **Modern Architecture**: Cloud-ready, API-first design
- **User-Centric**: Intuitive workflows that match how safety professionals work

---

## 3. Technical Architecture Overview

### 3.1 Technology Stack (Recommended)

```
┌─────────────────────────────────────────────────────────────┐
│                    PRESENTATION LAYER                        │
│  Desktop App (Electron) / Web App (React) / Mobile (React Native) │
└─────────────────────────────────────────────────────────────┘
                              │
┌─────────────────────────────────────────────────────────────┐
│                    APPLICATION LAYER                         │
│  Node.js/TypeScript or Python/FastAPI                        │
│  ┌─────────┐ ┌─────────┐ ┌─────────┐ ┌─────────┐           │
│  │ Auth    │ │Workflow │ │ E2B     │ │ Audit   │           │
│  │ Service │ │ Engine  │ │Generator│ │ Service │           │
│  └─────────┘ └─────────┘ └─────────┘ └─────────┘           │
└─────────────────────────────────────────────────────────────┘
                              │
┌─────────────────────────────────────────────────────────────┐
│                    DATA LAYER                                │
│  PostgreSQL (Primary) + Redis (Cache/Sessions)               │
└─────────────────────────────────────────────────────────────┘
                              │
┌─────────────────────────────────────────────────────────────┐
│                    INTEGRATION LAYER                         │
│  FDA ESG Gateway │ Email Service │ External APIs             │
└─────────────────────────────────────────────────────────────┘
```

### 3.2 Core Data Model

```
┌─────────────┐     ┌─────────────┐     ┌─────────────┐
│    Case     │────▶│   Patient   │     │   Product   │
│   (ICSR)    │     │             │     │  (Suspect)  │
└─────────────┘     └─────────────┘     └─────────────┘
      │                                        │
      │             ┌─────────────┐            │
      └────────────▶│   Event     │◀───────────┘
                    │  (Reaction) │
                    └─────────────┘
      │
      ▼
┌─────────────┐     ┌─────────────┐     ┌─────────────┐
│  Reporter   │     │ Attachment  │     │ Submission  │
│             │     │             │     │   History   │
└─────────────┘     └─────────────┘     └─────────────┘
```

### 3.3 Key Design Principles

1. **Modularity**: Each component is independently testable and deployable
2. **Compliance by Design**: Audit trails, validation, and security built into core
3. **Extensibility**: Plugin architecture for terminology, integrations
4. **Offline Capability**: Core functions work without network (Phase 1)
5. **API-First**: All functionality exposed via REST/GraphQL APIs

---

## 4. Development Phases

### Phase Overview

| Phase | Name | Duration | Key Deliverables |
|-------|------|----------|------------------|
| 1 | Core ICSR Submission (MVP) | 3-4 months | ICSR forms, E2B(R3) XML generation, local save |
| 2 | ESG Integration | 2-3 months | FDA gateway connectivity, submission tracking |
| 3 | Multi-User & Workflow | 2-3 months | Authentication, RBAC, approval workflows |
| 4 | Non-Expedited & PSR | 2-3 months | Periodic reports, batch submission |
| 5 | Enhanced Data Management | 2-3 months | MedDRA coding, duplicate detection, import |
| 6 | Premarketing (IND) Reports | 2 months | Clinical trial safety reports |
| 7 | Cosmetics & Multi-Regulatory | 2 months | E2B(R2) for cosmetics, MoCRA compliance |
| 8 | Analytics & Reporting | 2-3 months | Dashboards, KPIs, trend analysis |
| 9 | Advanced Integrations | 3-4 months | REST API, PV database connectors |
| 10 | Cloud/SaaS & Enterprise | 3-4 months | Multi-tenant, SSO, scalability |
| 11 | E2B(R2) Transition Support | 1-2 months | Legacy format support, migration tools |
| 12 | Safety Reporting Portal | 1-2 months | SRP fallback integration |

### Phase Dependencies

```
Phase 1 (MVP)
    │
    ▼
Phase 2 (ESG)
    │
    ▼
Phase 3 (Multi-User) ──────────┐
    │                          │
    ▼                          ▼
Phase 4 (PSR)            Phase 6 (IND)
    │                          │
    ▼                          │
Phase 5 (Data Mgmt) ◀──────────┘
    │
    ├──▶ Phase 7 (Cosmetics)
    │
    ├──▶ Phase 8 (Analytics)
    │
    ▼
Phase 9 (Integrations)
    │
    ▼
Phase 10 (Cloud/SaaS)
    │
    ├──▶ Phase 11 (E2B R2)
    │
    └──▶ Phase 12 (SRP)
```

---

## 5. E2B(R3) Data Structure

### 5.1 ICSR Components (ICH E2B R3)

The E2B(R3) standard defines the structure for Individual Case Safety Reports:

```
ICSR Message
├── Message Header (M.1)
│   ├── Message Identifier
│   ├── Message Sender/Receiver
│   └── Message Date
│
├── Safety Report (A)
│   ├── Report Identification (A.1)
│   ├── Primary Source (A.2)
│   ├── Sender Information (A.3)
│   └── Literature Reference (A.4)
│
├── Patient Information (B)
│   ├── Patient (B.1)
│   │   ├── Age/Birth Date
│   │   ├── Weight/Height
│   │   └── Sex
│   ├── Medical History (B.1.7)
│   ├── Past Drug History (B.1.8)
│   ├── Death (B.1.9)
│   ├── Parent (B.1.10)
│   └── Reaction/Event (B.2)
│       ├── MedDRA Coding
│       ├── Onset/Duration
│       ├── Outcome
│       └── Seriousness Criteria
│
├── Drug Information (B.4)
│   ├── Drug Characterization
│   ├── Medicinal Product
│   ├── Dosage Information
│   ├── Drug-Reaction Matrix
│   └── Additional Information
│
└── Narrative Summary (B.5)
```

### 5.2 Key Data Elements

| Section | Element | Description | Required |
|---------|---------|-------------|----------|
| A.1.0.1 | Safety Report ID | Unique case identifier | Yes |
| A.1.2 | Report Type | Initial, Follow-up, Nullification | Yes |
| A.2.1.4 | Reporter Qualification | HCP, Consumer, Other | Yes |
| B.1.1 | Patient Initials | Anonymized identifier | Conditional |
| B.1.2.2 | Patient Age | At time of reaction | Conditional |
| B.2.i.1 | Reaction MedDRA PT | Coded adverse event | Yes |
| B.2.i.7.2 | Seriousness Criteria | Death, hospitalization, etc. | Yes |
| B.4.k.2.1 | Drug Product Name | Suspect medication | Yes |
| B.5.1 | Case Narrative | Free text summary | Yes |

---

## 6. Regulatory Compliance Requirements

### 6.1 21 CFR Part 11 Compliance

| Requirement | Implementation |
|-------------|----------------|
| **Electronic Signatures** | Unique user ID + password, linked to records |
| **Audit Trail** | Immutable log of all changes with timestamp, user, old/new values |
| **Access Controls** | Role-based permissions, authentication |
| **System Validation** | Documented testing, validation protocols |
| **Record Integrity** | Checksums, encryption, backup procedures |

### 6.2 Data Privacy (HIPAA)

- Patient data must be de-identified or properly protected
- Minimum necessary principle for data access
- Encryption at rest and in transit
- Access logging for PHI

### 6.3 FDA Submission Requirements

- E2B(R3) XML schema compliance
- Valid MedDRA coding for reactions
- ESG account and credentials
- Digital certificates for transmission

---

## 7. Integration Points

### 7.1 External Systems

| System | Purpose | Phase |
|--------|---------|-------|
| FDA ESG | ICSR submission gateway | 2 |
| MedDRA | Adverse event terminology | 5 |
| WHO Drug Dictionary | Drug coding | 5 |
| SMTP/Email Service | Notifications | 3 |
| SSO Providers | Enterprise authentication | 10 |
| PV Databases | Argus, ArisGlobal integration | 9 |

### 7.2 API Design

```yaml
# Core API Endpoints (RESTful)
/api/v1/
  cases/
    GET    /                 # List cases
    POST   /                 # Create case
    GET    /{id}             # Get case details
    PUT    /{id}             # Update case
    DELETE /{id}             # Delete case (admin)
    POST   /{id}/validate    # Validate case
    POST   /{id}/submit      # Submit to FDA
    GET    /{id}/history     # Audit history
    GET    /{id}/xml         # Generate E2B XML
  
  submissions/
    GET    /                 # Submission history
    GET    /{id}             # Submission details
    POST   /{id}/retry       # Retry failed
  
  users/                     # Phase 3+
  reports/                   # Phase 8+
```

---

## 8. Quality & Testing Strategy

### 8.1 Testing Pyramid

```
         ┌─────────────┐
         │    E2E      │  10%
         │   Tests     │
         ├─────────────┤
         │ Integration │  20%
         │   Tests     │
         ├─────────────┤
         │    Unit     │  70%
         │   Tests     │
         └─────────────┘
```

### 8.2 Test Categories

| Category | Scope | Tools |
|----------|-------|-------|
| Unit | Individual functions, classes | Jest, Pytest |
| Integration | API endpoints, database | Supertest, TestContainers |
| E2E | User workflows | Playwright, Cypress |
| Security | Vulnerability scanning | OWASP ZAP, npm audit |
| Performance | Load testing | k6, Artillery |
| Compliance | 21 CFR Part 11 validation | Custom validation suite |

### 8.3 Code Quality Standards

- Test coverage minimum: 80%
- ESLint/Prettier for code formatting
- TypeScript strict mode
- Pre-commit hooks for validation
- PR reviews required for all changes

---

## 9. Deployment Strategy

### 9.1 Environments

| Environment | Purpose | Data |
|-------------|---------|------|
| Development | Feature development | Mock/synthetic |
| Testing | QA and integration | Sanitized production-like |
| Staging | Pre-production validation | Production mirror |
| Production | Live system | Real data |

### 9.2 CI/CD Pipeline

```
Code Commit
    │
    ▼
┌─────────────────┐
│  Lint & Format  │
└────────┬────────┘
         │
    ▼
┌─────────────────┐
│   Unit Tests    │
└────────┬────────┘
         │
    ▼
┌─────────────────┐
│  Build & Scan   │
└────────┬────────┘
         │
    ▼
┌─────────────────┐
│Integration Tests│
└────────┬────────┘
         │
    ▼
┌─────────────────┐
│ Deploy Staging  │
└────────┬────────┘
         │
    ▼
┌─────────────────┐
│   E2E Tests     │
└────────┬────────┘
         │
    ▼
┌─────────────────┐
│Deploy Production│ (manual approval)
└─────────────────┘
```

---

## 10. Project Conventions

### 10.1 File Structure

```
faers-app/
├── src/
│   ├── api/                 # API routes and controllers
│   ├── services/            # Business logic
│   ├── models/              # Data models and schemas
│   ├── repositories/        # Database access layer
│   ├── utils/               # Shared utilities
│   ├── validators/          # Input validation
│   ├── e2b/                 # E2B XML generation
│   └── integrations/        # External service integrations
├── tests/
│   ├── unit/
│   ├── integration/
│   └── e2e/
├── docs/
│   ├── requirements/        # Phase requirements
│   ├── api/                 # API documentation
│   └── architecture/        # Design documents
├── scripts/                 # Build and utility scripts
├── config/                  # Configuration files
└── migrations/              # Database migrations
```

### 10.2 Naming Conventions

| Type | Convention | Example |
|------|------------|---------|
| Files | kebab-case | `case-service.ts` |
| Classes | PascalCase | `CaseService` |
| Functions | camelCase | `createCase()` |
| Constants | UPPER_SNAKE | `MAX_RETRY_COUNT` |
| Database Tables | snake_case | `case_submissions` |
| API Endpoints | kebab-case | `/api/v1/case-submissions` |

### 10.3 Git Workflow

- **Main branch**: Production-ready code
- **Develop branch**: Integration branch
- **Feature branches**: `feature/phase-X-description`
- **Bugfix branches**: `bugfix/issue-description`
- Squash merges for clean history
- Semantic commit messages: `feat:`, `fix:`, `docs:`, `refactor:`

---

## 11. Success Metrics

### 11.1 Phase Completion Criteria

Each phase must meet:
- [ ] All requirements implemented and tested
- [ ] Test coverage ≥ 80%
- [ ] No critical/high security vulnerabilities
- [ ] Documentation complete
- [ ] User acceptance testing passed
- [ ] Performance benchmarks met

### 11.2 Application KPIs

| Metric | Target |
|--------|--------|
| XML Generation Time | < 2 seconds |
| Submission Success Rate | > 99% |
| System Uptime | 99.9% |
| User Error Rate | < 5% |
| Regulatory Compliance | 100% |

---

## 12. Reference Documentation

### 12.1 FDA Resources

- [FDA E2B(R3) Implementation Guide](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug)
- [FAERS Electronic Submissions](https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions)
- [21 CFR Part 11 Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application)

### 12.2 ICH Guidelines

- ICH E2B(R3): Electronic Transmission of ICSRs
- ICH E2D: Post-Approval Safety Data Management
- ICH M2: Electronic Standards for Transmission

### 12.3 Technical Standards

- MedDRA (Medical Dictionary for Regulatory Activities)
- WHO Drug Dictionary
- ISO 8601 (Date/Time formats)
- ISO 3166 (Country codes)

---

## Next Steps

Proceed to **Phase 1 Requirements** (`01_Phase1_Core_ICSR_MVP.md`) for detailed implementation specifications.
